149,988 members

Skip to content. | Skip to navigation

News

High cost drugs

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

High cost drugs

A number of high cost drugs are excluded from the payment by results (PbR) tariff.


They are typically specialist and their use is concentrated in a relatively small number of centres rather than evenly across all trusts that carry out activity in the relevant healthcare resource groups (HRG). These drugs would therefore not be fairly reimbursed if they were funded through the tariff. For all excluded activity, commissioners and providers should agree local prices.

The DH has published guidelines indicating  drugs that may be considered by the high cost drug steering group for inclusion on the exclusion list.